Eyenovia, Inc. announced on October 16, 2024, that results from its successful Phase 3 study (CPN-302) of clobetasol propionate suspension 0.05% would be presented at the American Academy of Ophthalmology (AAO) 2024 Expo.
The presentation, scheduled for October 19-21, 2024, details the study that led to FDA approval of clobetasol for post-surgical ocular inflammation and pain. The results demonstrated the magnitude and speed of inflammation and pain relief as early as four days post-surgery compared to placebo.
The study also showed a more rapid improvement in visual acuity and a desirable safety profile for clobetasol. This data reinforces the product's value following its U.S. commercial launch on September 26, 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.